Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.36 |
| ▸ | GLP1R | P43220 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035937 | 0.80 | GLP1R (0.37) | PTGS2PTGS1GPR55GLP1R | |
| SCHEMBL15035942 | 0.79 | GLP1R (0.46) | PTGS2GLP1RNR1H2NR1H3 | |
| SCHEMBL16248179 | 0.79 | S100A9 (0.42) | PTGS2PTGS1GPR55GLP1R | |
| SCHEMBL12506988 | 0.76 | PTGS2 (0.44) | SCDPTGS2PTGS1GPR55KIF11 | |
| SCHEMBL12414666 | 0.75 | PANK3 (0.37) | GLP1RNR1H3 | |
| SCHEMBL31002316 | 0.74 | PTGS2 (0.40) | SCDPTGS2PTGS1GPR55KIF11 | |
| SCHEMBL18125538 | 0.74 | MAP4K4 (0.42) | SCDPTGS2 | |
| SCHEMBL2737358 | 0.72 | AGBL2 (0.32) | — | |
| SCHEMBL15044958 | 0.71 | PTGS2 (0.39) | PTGS2KIF11 | |
| SCHEMBL12041152 | 0.71 | CCR1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | SCD 1316/4885PTGS2 2208/4885PTGS1 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.